INTRODUCTION
Glioblastomas (GBMs) are fatal tumors with florid vascularization that correlates with tumor malignancy and clinical prognosis (Norden et al., 2009) . Targeting endothelial cells (ECs) has been a major focus of antiangiogenic therapeutics, although tumor vessels consist of two distinct but interdependent cellular compartments: ECs and pericytes Carmeliet and Jain, 2011) . However, most current therapies targeting ECs are not curative and may transform tumor growth pattern toward a more invasive phenotype in GBMs (Pà ez- Ribes et al., 2009) , suggesting that targeting ECs alone is not sufficient for effective tumor control. Therefore, further insights into tumor vascular development and maintenance have direct translational implications.
Vascular pericytes play critical roles in various physiological contexts, including support of vascular structure and function, maintenance of blood-brain barrier, facilitation of vessel maturation, and initiation of vessel sprouting (Armulik et al., 2010; Bell et al., 2010; Bergers and Song, 2005; Winkler et al., 2011) . Pericytes and ECs communicate with each other by direct physical contact and reciprocal paracrine signaling to maintain vessel integrity and function (Franco et al., 2011; Carmeliet and Jain, 2011; Song et al., 2005) . Altered association between pericytes and ECs has been shown in tumor vessels (Carmeliet and Jain, 2011; Winkler et al., 2011) . Tumor vessels with less pericyte coverage appear more vulnerable to radiation and chemotherapy, suggesting that pericytes are critical to protect ECs and may promote therapeutic resistance (Bergers et al., 2003; Franco et al., 2011) . When therapies target ECs in tumors, the pericyte network often maintains a functional core of pre-existing blood vessels (Carmeliet and Jain, 2011) . The tumor vasculature frequently exhibits structural and functional abnormality with irregular pericytes on endothelial tubules. The pericyte-EC interaction also differs substantially between tumors and normal tissues (Morikawa et al., 2002; Winkler et al., 2011) . However, the mechanisms underlying the abnormality and difference are poorly understood. To better understand the vascular development and maintenance in tumors and lay the foundation for improved targeting therapy, it is essential to determine the interplay between cancer cells and vascular compartments.
GBMs display remarkable cellular hierarchies with tumorigenic glioma stem cells (GSCs) at the apex (Bao et al., 2006a; Calabrese et stem cell (CSC) model remains controversial for some tumor types (Magee et al., 2012) . We previously demonstrated that GSCs promote tumor angiogenesis through elevated expression of vascular endothelial growth factor (VEGF) (Bao et al., 2006b ). This study has been extended by others (Ehtesham et al., 2009; Folkins et al., 2009) . GSCs are often located in perivascular niches and interact with ECs in a bidirectional manner (Bao et al., 2006b; Calabrese et al., 2007) . Within this context, there was an excitement generated by reports suggesting that GSCs may transdifferentiate into ECs (Ricci-Vitiani et al., 2010; Soda et al., 2011; Wang et al., 2010) . These reports have been controversial because the frequency of GSC-EC conversion was not defined, and ECs do not contain cancer genetic alterations in human GBMs (Kulla et al., 2003; Rodriguez et al., 2012) . Because pericytes are physically proximal to ECs on vessels, distinguishing ECs and pericytes by location alone poses a challenge. A complementary or competing hypothesis would be a lineage commitment of GSCs to vascular pericytes. There are important reasons to consider GSCs as potential pericyte progenitors. GSCs have the ability to undergo mesenchymal differentiation (deCarvalho et al., 2010; Ricci-Vitiani et al., 2008) . GSCs share properties with neural stem cells (NSCs) that display the potential to transdifferentiate into pericytes (Ii et al., 2009; Morishita et al., 2007) . Further, pericytes are similar to mesenchymal stem cells (MSCs) (Crisan et al., 2008) . Thus, we investigated the potential of GSCs to generate vascular pericytes and contribute to the remodeling of perivascular niches and determined the significance of GSC-derived pericytes (G-pericytes) in maintaining functional vessels to support GBM tumor growth.
RESULTS

GSCs Are Able to Assume a Pericyte Lineage In Vitro
To investigate a potential lineage link between GSCs and pericytes, we initially examined the capacity of GSCs to differentiate into pericytes in vitro. GSCs were isolated from GBM tumors and validated through functional assays (self-renewal, multipotency, and tumor formation) as previously described (Bao et al., 2006a; Guryanova et al., 2011) . Immunofluorescent (IF) staining of freshly sorted GSCs from primary GBMs and the GSC-generated tumorspheres demonstrated SOX2 expression but complete absence of the pericyte markers a smooth muscle actin (a-SMA) and NG2 (Figures S1A and S1B available online), supporting a lack of contamination of GSC populations by pericytes. After GSCs or tumorspheres were induced for differentiation, the differentiated cells contained a fraction (4%-11%) of cells expressing multiple pericyte markers (a-SMA, NG2, CD248, and CD146) (Figures S1C-S1E). To further determine GSC ability to assume a pericyte lineage, we examined the cellular fate of single GSC-derived tumorsphere that did not contain any cell expressing pericyte markers ( Figure 1A ). Upon differentiation, cells derived from the single GSC-derived tumorsphere contained a fraction of cells expressing pericyte markers ( Figure 1B ). To rule out potential contamination of host-derived pericyte progenitors in xenograft-derived GSCs, we performed secondary sorting of enriched GSCs with positive selection for the human cell-specific surface antigen TRA-1-85 and negative selection for the pericyte marker CD146. We confirmed that the single GSC-generated spheres derived from the resorted GSCs (SOX2 + ) did not contain any cell expressing pericyte markers ( Figure S1F ), whereas differentiated cells derived from the single GSC-derived sphere contained pericyte-marker-expressing cells ( Figure S1G ). These pericyte-marker-positive cells also expressed the human-cell-specific nuclear antigen NuMA (Figure S1G) , confirming that these pericytes were derived from human GSCs, but not from murine pericytes or their progenitors.
Collectively, these data demonstrate that GSCs have the capacity to assume a pericyte lineage in vitro.
GSCs Give Rise to Vascular Pericytes in GBM Xenografts In Vivo
To extend the lineage analysis of GSCs in vivo, we examined the origin of pericytes in GBM xenografts and found that pericytes (CD146   +   CD248 + ; 2.63%-6.14% of total cells) sorted from the xenografts were largely positive for human NuMA and TRA-1-85 (Figures S1H, S1I, and S1L). In contrast, purified ECs (CD31 + CD105 + ) from GBM xenografts were completely negative for human NuMA and TRA-1-85 (Figures S1J-S1L). We then performed a lineage tracing study by transducing GSCs with GFP constitutive expression and implanted the GSCs orthotopically to establish xenografts. Tumor sections of the xenografts derived from the green fluorescent protein (GFP)-labeled GSCs were immunostained for an EC marker (CD31) and several pericyte markers (a-SMA, Desmin, NG2, CD146, CD248, Ang1, CD13, and platelet-derived growth factor receptor b [PDGFRb]) because these pericyte markers are expressed in normal brain and primary . No tumor showed GFP-positive ECs, but most tumor vessels were adorned with GFP-positive cells with typical pericytic location and morphology on the vascular external surface ( Figures 1C and 1D ). IF analyses of pericyte markers further confirmed that expression of pericyte markers (Desmin, a-SMA, NG2, PDGFRb, CD248, and CD146) overlapped with GFP in the majority (mean 78%, range 57%-89%) of pericytes (Figures 2A and 2B; Figures S2D and S2E) , indicating that the majority of vascular pericytes were derived from GSCs. We validated this result in 21 GBM xenografts using GFP-labeled GSCs isolated from 12 primary GBMs and 9 GBM xenografts, suggesting that the contribution of GSCs to pericytes is a common event during GBM growth. Notably, a minor fraction (mean 22%, range 11%-43%) of vascular pericytes in the GBM xenografts did not overlap with GFP expression, indicating that these pericytes were host derived. Most tumor vessels had a mixture of GSC-and hostderived pericytes (Figure 2A ). Taken together, these data demonstrate that GSCs have the capacity to generate the majority of vascular pericytes in GBM xenografts.
Peritumoral Brain Vessels Contain G-Pericytes
Because GBMs commonly invade into normal brain, we examined whether GSCs contribute to vascular pericytes in peritumoral brain. We found that a subset of vessels in peritumoral brain adjacent to the GFP-labeled GSC xenograft also contain GFP-positive pericytes ( Figure 1E ). IF analyses validated a fraction of vessels coexpressing pericyte markers and GFP and in brain tissue near the GFP tumor ( Figure 2C ). These data indicate that GSCs can also give rise to pericytes in the peritumoral brain. Notably, G-pericytes (GFP + ) were detectable not only in peritumoral brain but also in tumor-free brain up to 0.86 mm distant from the tumor edge, suggesting that GSCs were recruited by ECs in the peritumoral brain to generate pericytes. Thus, GSCs also generate vascular pericytes in the peritumoral brain.
Validation of G-Pericytes by Lineage-Specific Fluorescent Reporters
To provide direct evidence validating GSC capacity to generate pericytes in vivo, we performed in vivo cell lineage tracing of GSCs with a pericyte marker (Desmin or a-SMA) promoterdriven expression of GFP or mCherry, which served as fluorescent reporters of pericyte lineage. We cloned the human Desmin promoter (Li and Paulin, 1991 ) and a-SMA core promoter (Keogh et al., 1999; Nakano et al., 1991) and then generated lentiviral constructs for the Desmin promoter-driven GFP expression (DesPro-GFP) or a-SMA promoter-driven mCherry expression (aSMAPro-mCherry). We confirmed that the cloned Desmin and a-SMA promoters were functional and pericyte specific because GFP or mCherry expression occurred specifically in human brain vascular pericytes (HBVPs) (Figure S3A, left) . We then implanted DesPro-GFPtransduced GSCs into mouse brains and examined tumor vessels by IF analysis. DesPro-driven GFP expression specifically marked perivascular cells that expressed pericyte markers, including Desmin, NG2, PDGFRb, CD248, Ang1, and CD13 ( Figures 3A-3C ), validating that GSCs generated vascular pericytes in the GBM xenografts. The G-pericytes also expressed the gap junction protein connexin45 (Cx45) that is often localized at pericyte-EC contacts ( Figures 3D and 3E) . Notably, GFP-positive cells were mainly located in perivascular regions close to vessels but rarely detected in regions distant from vessels in tumors ( Figure 3F ). We further performed an additional pericyte lineage tracing of GSCs cotransduced with DesPro-GFP and aSMAPro-mCherry and detected coexpression of mCherry and GFP in perivascular cells (Figures 3G and 3H) . GFP + perivascular cells were abundant around vessels and the majority of pericyte-marker-positive cells (>83%) expressed GFP ( Figures 3A-3F ), confirming that GSCs generated the majority of pericytes in these tumors.
Tumor pericytes often exhibit abnormal morphologies, sometimes extending their processes away from the endothelium (Morikawa et al., 2002) . The G-pericytes often displayed such irregular morphology ( Figures 3A and 3F ). Recent appreciation of intertumoral heterogeneity of GBMs has informed a mesenchymal subtype in contrast to proneural and classical subtypes (Verhaak et al., 2010) . Interestingly, in vivo lineage tracing showed that mesenchymal GSCs have significantly greater ability to generate pericytes than classic and proneural GSCs in xenografts (Figures S3B and S3C; Table S1 ). Collectively, these data provide direct evidence demonstrating that GSCs have the capacity to generate pericytes in vivo.
Because our in vivo cell fate tracing of GSCs with GFP constitutive expression failed to detect GSC-derived ECs ( Figures 1C  and 1D ), we performed the cell lineage tracing of GSCs with an EC marker (CD31 or CD105) promoter-driven GFP expression to directly address whether GSCs generate ECs. We cloned the human CD105 (endoglin) promoter (Ríus et al., 1998) and the CD31 (PECAM-1) promoter restricted to ECs (Almendro et al., 1996; Gumina et al., 1997) and then generated lentiviral constructs for conditional GFP expression driven by CD31 or CD105 promoter (CD31Pro-GFP or CD105Pro-GFP). We validated that the cloned CD31 and CD105 promoters were functional and EC specific because CD31Pro-or CD105Pro-driven GFP expression specifically occurred in ECs (human brain microvessel endothelial cells [HBMECs]) ( Figure S3A , right). To perform EC lineage tracing of GSCs, GSCs with CD31Pro-GFP or CD105Pro-GFP were orthotopically implanted into mouse brains. In confirmation with our earlier studies, no GFP expression was detectable in tumor ECs marked by CD31 and Glut1 staining ( Figures S3D and S3E ), further ruling out the possibility of GSC-derived ECs in GBM xenografts.
To further characterize the G-pericytes, we examined pericyte marker expression in G-pericytes and HBVP pericytes. We isolated G-pericytes by sorting GFP + CD146 + cells from GBM xenografts derived from the DesPro-GFP-GSCs. Comparative RT-PCR analyses of key pericyte markers (a-SMA, Desmin, CD248, NG2, CD146, and PDGFRb) in the sorted G-pericytes and HBVPs confirmed similar marker expression in the GBM xenografts ( Figure S4A) . To address whether G-pericytes still express GSC markers after lineage switching, we examined expression of several putative GSC markers (SOX2, OLIG2, CD133, and Nestin) and pericyte markers in sorted GSCs (CD15 + L1CAM + ) and G-pericytes (GFP + CD146 + ). RT-PCR analyses showed that G-pericytes no longer express the GSC markers ( Figure S4B ). This result was confirmed by IF staining of SOX2, OLIG2, or Nestin on frozen sections of the DesPro-GFP-GSC xenografts. Consistently, GFP expression was turned on specifically in perivascular cells that rarely (<0.8%) expressed SOX2, OLIG2, or Nestin ( Figure S4C , S4D, and S4F). In contrast, the SOX2, OLIG2, or Nestin-expressing cells (GSCs) are localized near perivascular niches ( Figure S4C and S4D) . The mutually exclusive expression of GSC and pericyte markers suggests that GSCs undergo differentiation to generate G-pericytes rather than being a GSC subpopulation adjacent to ECs in GBM tumors. In addition, G-pericytes do not express astrocyte markers such as glial fibrillary acidic protein (GFAP) and S100b ( Figures S4A, S4E, and S4F ), indicating that G-pericytes are not a subpopulation of astrocytes. Consistently, pericytes and astrocytes are distinct cell populations without overlapping expression of specific markers in primary GBMs ( Figure S4G ). These data demonstrate that G-pericytes are unique cells expressing specific pericyte markers. Glut1 but did not share the GSC genetic alterations ( Figure S5C and S5D). These results support a tumor source for pericytes, but not for ECs in human primary GBMs.
Pericytes in Primary GBMs
To further address whether pericytes in endogenous GBMs are derived from cancer cells, we examined pericytes in the genetically engineered mouse GBMs (Nestin-tva/Ink4a/Arf À/À / HA-PDGFB models; Hambardzumyan et al., 2009) . IF staining of hemagglutinin-tagged platelet-derived growth factor B (HA-PDGFB) and pericyte markers (Desmin, NG2, CD248, or a-SMA) showed that a significant fraction (mean 63%) of tumor pericytes expressed HA-PDGFB, supporting a tumor origin (Figure 4E, 4F ; data not shown). In contrast, staining of EC markers (CD31 or Glut1) and HA-PDGFB showed no tumor-cell-derived ECs in these mouse GBMs ( Figure S5E ). These data demonstrate that pericytes in the genetically engineered mouse GBMs are also largely derived from neoplastic cells.
Selective Elimination of G-Pericytes Disrupts Tumor Vessels and Inhibits Tumor Growth
To determine the functional significance of G-pericytes, we examined effects of selective elimination of G-pericytes on vessels and tumor growth. GSCs were transduced with Desmin-promoter-driven expression of herpes simplex virus thymidine kinase (HsvTK) ( Figure 5A ) to achieve conditional HsvTK expression in G-pericytes. Because HsvTK metabolizes ganciclovir (GCV) into a toxic agent specifically in cells expressing HsvTK (Culver et al., 1992) , G-pericytes expressing HsvTK should be sensitive to GCV and thus eliminated by GCV treatment. To confirm selective killing of G-pericytes expressing Desmin-promoter-driven HsvTK by GCV treatment, we generated a construct for coexpression of HsvTK and GFP under the same promoter (DesPro-TK-GFP) ( Figures 5A and S6A) . As expected, after the DesPro-TK-GFP-transduced GSCs were induced to differentiate, GFP was expressed in a fraction of differentiated cells (G-pericytes) ( Figure S6B ). Apoptotic detection showed that GCV treatment selectively induced apoptosis in cells coexpressing GFP and HsvTK ( Figure S6C ). These data indicate that selective elimination of G-pericytes is achievable by using Desmin-promoter-driven HsvTK conditional expression with GCV treatment.
To examine the impact of selective targeting of G-pericytes on tumor vessels, we implanted DesPro-TK-GFP-GSCs into mouse brains. Mice bearing the tumors were treated with vehicle control or GCV daily to induce HsvTK-mediated toxicity to G-pericytes. Apoptotic detection by TUNEL staining demonstrated that GCV treatment for 3 days selectively induced cell death in G-pericytes (GFP + ) in vivo ( Figure 5B ). Further, GCV treatment for 1 week caused almost a complete depletion of G-pericytes, collapse of vessel lumens, and disruption of endothelial walls in GBM tumors ( Figures 5C, 5D, S6D and S6E) . Moreover, measurement of vascular function by fluorescein isothiocyanate (FITC)-conjugated mega-dextran showed that GCV treatment for 1 week to deplete G-pericytes severely attenuated vascular function in the DesPro-TK-GSC xenografts, because perfusion of FITCmega-dextran into the tumors was dramatically reduced (Figures 5E, 5F, S6F and S6G) . Collectively, these data demonstrate that selective elimination of G-pericytes potently disrupts vascular structure and function in GBM tumors.
To evaluate the impact of selective targeting of G-pericytes on tumor growth, we initially used subcutaneous tumor experiments to track sequential tumor volumes. The established subcutaneous tumors derived from the DesPro-TK-GFP-GSCs were treated with GCV or vehicle control for 3 weeks. GCV treatment caused significant regression of the tumors ( Figures 5G and 5H ), indicating that selective elimination of G-pericytes by HsvTKinduced GCV toxicity inhibited tumor growth. To further validate Table S1 . this result in orthotopic tumors, we transduced GSCs either with DesPro-GFP (control) or DesPro-TK and implanted these GSCs into mouse brains to establish GBM xenografts. Both groups of mice bearing the tumors were administered with GCV to eliminate the G-pericytes expressing HsvTK. GCV treatment for 2 weeks caused extensive vessel regression in GBM tumors derived from DesPro-TK-GSCs, but not from DesPro-GFPGSCs ( Figures S6H and S6I) . Moreover, GCV treatment for 3 weeks markedly inhibited intracranial tumor growth in GBM xenografts derived from DesPro-TK-GSCs, but not in control tumors from DesPro-GFP-GSCs ( Figures 5I and 5J ). Alternatively, treatment by GCV, but not vehicle control suppressed intracranial tumor growth in the GBM xenografts derived from DesPro-TK-GSCs ( Figure S6J ). As a consequence, GCV treatment significantly increased survival of animals implanted with the DesPro-TK-GSCs ( Figure 5K ). These data demonstrate that selective elimination of G-pericytes suppressed GBM tumor growth and malignant progression.
GSCs Are Recruited toward ECs via the SDF-1/CXCR4 Axis
To understand the mechanisms underlying GSC recruitment toward ECs, we examined whether GSCs can be recruited by HBMECs to support the maintenance of EC complexes in vitro. GSCs labeled with the green fluorescent tracer CFSE were mixed with HBMEC complexes labeled with the red fluorescent tracer CMTRX. Integration of GSCs-derived cells into EC complexes was detected on day 2 after cell mixing, and the integration stabilized the EC complexes for extended periods (2.6-fold) relative to EC complex alone ( Figure 6A ). To address whether pericyte lineage specification of GSCs can be induced by EC complexes, we cocultured GSCs with HBMECs and detected integration of G-pericytes by a-SMA staining ( Figure 6B ). Because the attachment of pericytes to ECs can be mediated through adherens junctions containing N-cadherin (Gerhardt et al., 2000) , we examined N-cadherin expression and found that N-cadherin was localized to the contact sites between G-pericytes (a-SMA + ) and EC complexes ( Figure 6B ).
To define the molecular mechanisms underlying GSC recruitment by ECs, we analyzed the effect of several chemotactic factors (SDF-1a, PDGFB, and transforming growth factor b [TGF-b]) secreted by HBMECs on GSC migration. We found that SDF-1 potently stimulated GSC migration ( Figures S7A  and S7B ), whereas PDGFB only modestly attracted GSCs. To further address whether HBMECs attract GSCs via SDF-1, we cocultured GSCs and HBMECs in separate chambers of transwells and detected that HBMECs potently attracted GSCs, an effect dependent on SDF-1 because an anti-SDF-1 antibody attenuated the effects (Figures S7C and S7D ). Because ECs in brain and GBMs constitutively express SDF-1 (Kokovay et al., 2010; Komatani et al., 2009) , we confirmed that abundant SDF-1 formed a gradient around vessels with greater SDF-1 proximal to vessels in brain and GBMs ( Figure S7E ).
Because SDF-1 is secreted by ECs and GSCs express the SDF-1 receptor CXCR4 (Ehtesham et al., 2009; Folkins et al., 2009) , we hypothesized that brain ECs may recruit GSCs at least in part through the SDF-1/CXCR4 axis. CXCR4 knockdown in GSCs reduced the recruitment of GFP-labeled GSCs to EC complexes ( Figures 6C and 6D ). In addition, an SDF-1 blocking antibody significantly reduced the integration of GFP-labeled GSCs into HBMEC complexes ( Figures S7F and S7G) . As a further confirmation, we examined the effect of a CXCR4 inhibitor (AMD3100) on GSC recruitment to EC complexes. AMD3100 treatment significantly reduced the integration of GSCs (CMTRX labeled, in red) into CFSE-labeled HBMECs (in green) (Figures S7H and S7I) .
To further determine whether GSC recruitment to ECs depends on the SDF-1/CXCR4 axis during tumor vascularization, GFP-labeled GSCs were transduced with shCXCR4 or nontargeting small hairpin RNA (shNT) and implanted into mouse brains. In shNT xenografts, tumor vessels were covered with abundant G-pericytes (GFP + and Desmin + ), whereas G-pericytes and total pericyte coverage on vessels was significantly reduced in shCXCR4 xenografts ( Figures 6E-6G ). Immunohistochemical (IHC) staining confirmed that CXCR4 knockdown significantly decreased vessel density in the tumors ( Figures  S7J and S7K) . Collectively, these data suggest that ECs recruit GSCs via the SDF-1/CXCR4 axis and that targeting this pathway reduces G-pericytes in GBMs.
TGF-b Induces Differentiation of GSCs into Pericytes
We next sought to understand the molecular mechanisms underlying the pericyte lineage specification of GSCs. To identify the potential factors inducing GSC differentiation into pericytes, we examined the effect of several EC-secreted cytokines (SDF-1, PDGFB, and TGF-b) on GSC differentiation into pericytes. Immunoblot analysis showed that TGF-b dominantly induced expression of a-SMA when GSCs were cultured in differentiation media (Figures 7A and 7B) . IF staining of multiple pericyte markers (NG2, a-SMA, CD146 and CD248) confirmed that TGF-b treatment increased the fraction of cells expressing pericyte markers in the differentiated cells (Figures 7C and 7D ; data not shown). Further, TGF-b treatment induced GFPexpressing cells in differentiated cells derived from DesPro-GFP-GSCs ( Figures 7E and 7F ). To address whether ECs induce GSC differentiation into pericytes through TGF-b, we cocultured DesPro-GFP-GSCs and HBMEC complexes and monitored GFP-expressing cells (G-pericytes) over time. GFP + cells were induced and integrated into EC complexes, an effect that was attenuated by incubation of the EC complexes with an anti-TGF-b antibody ( Figure 7G ). Immunoblot analysis validated that coculture of GSCs with HBMECs or their conditioned media induced expression of pericyte marker a-SMA in differentiated cells, an effect that was reduced by a TGF-b neutralizing antibody ( Figure 7H ). Collectively, these data demonstrate that HBMECs induce pericyte lineage specification of GSCs at least in part through TGF-b. Thus, the recruitment of GSCs toward ECs via the SDF-1/CXCR4 axis and the induction of GSC differentiation into pericytes by TGF-b are two events controlled by different molecular mechanisms ( Figure 7I ).
DISCUSSION
Pericytes play essential roles to maintain functional vessels to support tumor growth. Tumor pericytes are thought to be derived from their progenitors from the surrounding normal tissue or from the bone-marrow-derived cells homing in tumors after treatments (De Palma et al., 2005; Du et al., 2008) . In this study, we demonstrate that the majority of vascular pericytes in GBMs are derived from GSCs. Because G-pericytes express similar pericyte markers as normal brain vascular pericytes, GSCs function as pericyte progenitors and contribute to vasculature formation in GBMs. The ability of GSCs to generate vascular pericytes in vivo suggests that GSCs may actively remodel their microenvironment and create a supportive niche, permitting functional vessels to augment tumor growth without depending on the limited source of normal pericyte progenitors from surrounding tissues. Because NSCs can transdifferentiate into pericytes (Ii et al., 2009; Morishita et al., 2007) , a lineage link between NSCs and pericytes is present in normal tissues. Because GSCs share regulatory programs with NSCs, the plasticity of GSCs toward a pericyte lineage may be a product of aberrant developmental biology. Although previous reports suggest that GSCs may give rise to ECs in GBMs (Ricci-Vitiani et al., 2010; Soda et al., 2011; Wang et al., 2010) , such an event may be very rare because ECs in GBMs rarely carry the cancer genetic mutations as demonstrated in our study and others (Kulla et al., 2003; Rodriguez et al., 2012) . Moreover, our complementary lineage tracing studies failed to demonstrate GSC-derived ECs in vivo, although in the culture condition we occasionally observed rare EC-marker-expressing cells (<0.6%) in differentiated cells from GSCs. Because vascular pericytes closely attach to ECs and both cells appear very thin, prior studies may have missed the true identity of tumor-derived cells on vessels. Because both ECs and pericytes express Tie2 (De Palma et al., 2005) , the use of Tie2 promoter-driven HsvTK expression for targeting ''GSC-derived ECs'' (Ricci-Vitiani et al., 2010) directly demonstrated that GSCs give rise to pericytes rather than ECs in vivo. The contribution of GSCs to vascular pericytes requires GSC recruitment toward ECs. Because ECs in brain and GBMs express abundant SDF-1 forming chemoattractant gradient, the expression of CXCR4 (the receptor for SDF-1) in GSCs (Ehtesham et al., 2009; Folkins et al., 2009 ) may provide a paracrine loop for recruitment of GSCs toward ECs. A recent study showed that NSCs can be recruited to perivascular niches in normal brain through the CXCR4/SDF-1 axis (Kokovay et al., 2010) . The recruitment of pericyte progenitors to ECs in normal tissues also depends on SDF-1/CXCR4 signaling (Song et al., 2009) . SDF-1 expression has been proposed as one of the mechanisms underlying the resistance to antiangiogenic therapy in GBM trials (Batchelor et al., 2007) . Elevated SDF-1 signaling may enhance GSC recruitment toward ECs and increase G-pericyte coverage to protect tumor vessels, leading to resistance to antiangiogenic therapy.
The potent capacity of GSCs to generate vascular pericytes allows active vascularization in GBMs to support tumor growth. Because GSCs contribute to the majority of vascular pericytes in GBMs, G-pericytes may have a crucial role in mediating therapeutic resistance in GBMs. Because pericytes juxtacrine to ECs express significant levels of VEGF and other factors to support EC survival (Franco et al., 2011; Song et al., 2005; Winkler et al., 2011) , G-pericytes may protect ECs and render ECs less responsive to antiangiogenic agents in GBMs. Thus, targeting G-pericytes may synergize with current therapies targeting ECs to achieve more effective outcome. Because CSCs are present in other solid cancers (Magee et al., 2012) , it is important to determine whether CSCs can generate vascular pericytes in other malignant tumors with florid angiogenesis. Our studies demonstrate that GSCs not only interact with perivascular niches but also have the capacity to remodulate their microenvironment by contributing pericyte compartments of the neovasculature. Because selective elimination of G-pericytes potently disrupted vessels and inhibited tumor growth, therapeutic targeting of G-pericytes may have a significant impact on improving GBM treatment efficacy.
EXPERIMENTAL PROCEDURES
Isolation of GSCs and Non-Stem Tumor Cells from GBMs GBM surgical specimens were collected in accordance with a Cleveland Clinic Institutional Review Board-approved protocol. GSCs and non-stem tumor cells were derived from GBM tumors and functionally validated as described previously (Bao et al., 2006a; Guryanova et al., 2011) . For the detailed procedure, please see Extended Experimental Procedures.
Pericyte or EC-Specific Promoter-Driven Expression of GFP or mCherry Human Desmin promoter (312 bp) with an enhancer (284 bp) (Li and Paulin, 1991) , a-SMA promoter (262 bp) with an enhancer (123 bp) (Keogh et al., 1999; Nakano et al., 1991) , CD105 promoter plus enhancer (955 bp) (Ríus et al., 1998) , and CD31 promoter plus enhancer (887 bp) restricted to ECs (Almendro et al., 1996; Gumina et al., 1997) were cloned by PCR and confirmed by sequencing. The specific promoter with enhancer was inserted into pCDH-CMV-EF1-Puro lentiviral vector (System Biosciences) to replace the original CMV promoter. The ORF of GFP or mCherry was then inserted into the vector to generate lentiviral constructs. Lentiviruses were produced and tittered as described elsewhere (Guryanova et al., 2011) .
Cell Lineage Tracing of GSCs
To perform cell lineage tracing, GSCs were transduced with GFP or mCherry constitutive expression or conditional expression driven by the pericyte or EC-specific promoter through lentiviral infection and then transplanted into brains of athymic BALB/c nu/nu mice to establish xenografts as described elsewhere (Guryanova et al., 2011) . To trace cell lineage of GSCs in vivo, sections of mouse brains bearing the xenografts were immunostained for pericyte or EC markers and analyzed for GFP or mCherry expression. IF and IHC stainings were performed as described (Guryanova et al., 2011) . Tumor sections of the genetically engineered mouse GBMs were provided by Dr. Dolores Hambardzumyan. For detailed methods and the antibody information, please see Extended Experimental Procedures.
Selective Targeting of G-Pericytes in GBM Xenografts
GSCs were transduced with Desmin or CD31-promoter-driven expression of HsvTK, GFP, or HsvTK plus GFP through lentiviral infection and then transplanted into brains of athymic mice. Mice bearing the xenografts received GCV (Sigma-Aldrich) at 75 mg/kg/day or vehicle control daily through intraperitoneal injection. The xenografts were collected for IF and IHC staining and fluorescent analysis. To evaluate the targeting effect on animal survival, mice were maintained until the development of neurological signs.
HBVPs, HBMECs, and EC Complex Formation
HBVPs and HBMECs were obtained from ScienCell. HBMECs with low passage were used for coculture and endothelial complex formation assays as described (Bao et al., 2006b) . For the detailed procedure and the labeling of GSCs and HBMECs, please see Extended Experimental Procedures.
Statistical Analysis
All quantified data were statistically analyzed. Grouped data are presented as mean ± SD. The difference between experimental groups was assessed by one-way ANOVA or one-way ANOVA on ranks testing. For the animal survival experiments, log-rank survival analysis was performed.
For further details, please see Extended Experimental Procedures. 
SUPPLEMENTAL INFORMATION
